Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment
NCT ID: NCT01962181
Last Updated: 2013-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2013-10-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants
NCT01310439
Psychostimulants Effects on Brain Functional Connectivity in Youth With Attention Deficit Hyperactivity Disorder
NCT02318017
The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)
NCT01554046
Stimulant Effects on Brain Activity
NCT02453698
Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
NCT01063153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ritalin
Ritalin treatment at different doses
Ritalin
Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
Placebo
Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ritalin
Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects aged 18-50 years diagnosed with ADHD and treated with Ritalin regularly (at least once a week).
Exclusion Criteria
* Patients after traumatic head injury.
* Patients who are unable to express their consent to participate in the study.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Renana Eitan, MD
Role: PRINCIPAL_INVESTIGATOR
Hadassah Medical Organization
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Center
Jerusalem, Israel, Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Shahar Arzy, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RE0379-HMO-STILL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.